Contract Service Directory

Samsung Biologics





Company Headquarters

300 Songdo Bio Way, Yeonsu-gu,
Incheon, 21987
South Korea

Company Description

Samsung BioLogics is a full service provider of Quality driven cGMP contract manufacturing for the global biopharmaceutical industry. Our facilities are flexibly designed for cost effective production of monoclonal and recombinant drug substance and drug product. Our integrated services include cell line generation, process development, analytical services, clinical and commercial bulk cGMP manufacturing and fill finish services. Our commitment to provide the best Quality Assurance and Quality Control with worldwide regulatory compliance standards ensures dedicated support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.

Contract Service Directory

    Related Content

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Information Technology | Validation
      Samsung Biologics Achieves ISO27001 Certification

      Samsung Biologics Achieves ISO27001 Certification

      Becomes first CDMO to receive highly touted recognition for information security management.
      11.15.19

    • CPL

      CPL's David Tyler

      CPL's director of business development was on hand at Contract Pharma 2019.
      Contract Pharma

    • Bio News | Breaking News | Industry News | Information Technology
      Goodwin Bio Launches Digitization Initiative

      Goodwin Bio Launches Digitization Initiative

      Invests in a sophisticated electronic quality solution.
      11.11.19


    • Breaking News | Industry News
      Biogen, Samsung Bioepis Enter New Biosimilars Transaction

      Biogen, Samsung Bioepis Enter New Biosimilars Transaction

      Secures exclusive rights to commercialize ophthalmology biosimilars referencing Lucentis and Eylea
      11.07.19

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Samsung Biologics and Ichnos Sciences Ink Mfg. Deal

      Samsung Biologics and Ichnos Sciences Ink Mfg. Deal

      Samsung to manufacture drug substance for ISB 830 Phase 3 clinical trials and for potential future global commercial supply upon regulatory approval.
      11.05.19

    • Bio News | Breaking News | Facilities | Industry News
      Samsung BioLogics Expands Biomanufacturing Capabilities

      Samsung BioLogics Expands Biomanufacturing Capabilities

      Implements large scale N-1 perfusion for commercial application
      08.12.19


    • Bio News | Breaking News | Industry News | Promotions & Moves | QA/QC | Regulatory Affairs
      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Names Gerald Orehostky as vice president of quality and regulatory operations
      08.07.19

    • Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

      Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

      The CDMO will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy
      07.31.19

    • 21	Biogen

      21 Biogen

      Headquarters: Cambridge, MA twitter.com/biogenidec www.biogenidec.com Headcount: 7,800 Year Established: 2003 Revenues:  $13,453  (+10%) Net Income:  $4,431  (+75%) R&D:  $2,597   (+15%) Top Sellin…
      07.15.19


    • Promotions & Moves
      Pii Appoints Business Executives

      Pii Appoints Business Executives

      Ideus, Grellner and McFarlane to head market engagement and business management activities
      07.02.19